Fusion Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.6412
- Today's High:
- $2.76
- Open Price:
- $2.68
- 52W Low:
- $1.98
- 52W High:
- $5.63
- Prev. Close:
- $2.69
- Volume:
- 11801
Company Statistics
- Market Cap.:
- $185.60 million
- Book Value:
- 2.942
- Revenue TTM:
- $368000
- Operating Margin TTM:
- -27116.85%
- Gross Profit TTM:
- $-57434000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.13%
- Return on Equity TTM:
- -48.82%
Company Profile
Fusion Pharmaceuticals Inc had its IPO on 2016-03-14 under the ticker symbol FUSN.
The company operates in the Healthcare sector and Biotechnology industry. Fusion Pharmaceuticals Inc has a staff strength of 101 employees.
Stock update
Shares of Fusion Pharmaceuticals Inc opened at $2.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.64 - $2.76, and closed at $2.67.
This is a -0.74% slip from the previous day's closing price.
A total volume of 11,801 shares were traded at the close of the day’s session.
In the last one week, shares of Fusion Pharmaceuticals Inc have slipped by -8.87%.
Fusion Pharmaceuticals Inc's Key Ratios
Fusion Pharmaceuticals Inc has a market cap of $185.60 million, indicating a price to book ratio of 0.5939 and a price to sales ratio of 64.5141.
In the last 12-months Fusion Pharmaceuticals Inc’s revenue was $368000 with a gross profit of $-57434000 and an EBITDA of $-98690000. The EBITDA ratio measures Fusion Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fusion Pharmaceuticals Inc’s operating margin was -27116.85% while its return on assets stood at -25.13% with a return of equity of -48.82%.
In Q2, Fusion Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 94%.
Fusion Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fusion Pharmaceuticals Inc’s profitability.
Fusion Pharmaceuticals Inc stock is trading at a EV to sales ratio of 8.1968 and a EV to EBITDA ratio of 0.7009. Its price to sales ratio in the trailing 12-months stood at 64.5141.
Fusion Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $268.29 million
- Total Liabilities
- $17.09 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $710000
- Dividend Payout Ratio
- 0%
Fusion Pharmaceuticals Inc ended 2024 with $268.29 million in total assets and $0 in total liabilities. Its intangible assets were valued at $268.29 million while shareholder equity stood at $202.96 million.
Fusion Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $17.09 million in other current liabilities, in common stock, $-331328000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.02 million and cash and short-term investments were $198.10 million. The company’s total short-term debt was $5,357,000 while long-term debt stood at $34.49 million.
Fusion Pharmaceuticals Inc’s total current assets stands at $207.86 million while long-term investments were $28.42 million and short-term investments were $166.07 million. Its net receivables were $2.40 million compared to accounts payable of $2.06 million and inventory worth $5.67 million.
In 2024, Fusion Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $710000.
Comparatively, Fusion Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.67
- 52-Week High
- $5.63
- 52-Week Low
- $1.98
- Analyst Target Price
- $13.1
Fusion Pharmaceuticals Inc stock is currently trading at $2.67 per share. It touched a 52-week high of $5.63 and a 52-week low of $5.63. Analysts tracking the stock have a 12-month average target price of $13.1.
Its 50-day moving average was $3.37 and 200-day moving average was $3.74 The short ratio stood at 1.76 indicating a short percent outstanding of 0%.
Around 584.4% of the company’s stock are held by insiders while 7735.7% are held by institutions.
Frequently Asked Questions About Fusion Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.